Cullinan Therapeutics Inc (CGEM)
15.66
-2.41
(-13.34%)
USD |
NASDAQ |
Apr 19, 16:00
15.85
+0.19
(+1.21%)
After-Hours: 19:47
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 674.41M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 75.95% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.486 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Cullinan Oncology Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted oncology therapies without bias towards specific treatment modalities. Their mission centers on setting new standards of care for cancer patients by identifying high-impact cancer targets, defined as key oncogenic drivers or immune system activators. The company's strategy involves selecting optimal therapeutic modalities for these targets. Operating as a single reporting and operating segment, the company's core business is developing early-stage cancer therapeutics, aiming to address critical needs in oncology treatment. The company's pipeline consists of CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, CLN-617. |
| URL | https://www.cullinanoncology.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 14, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Cullinan Oncology Inc is a clinical-stage biopharmaceutical company that focuses on developing targeted oncology therapies without bias towards specific treatment modalities. Their mission centers on setting new standards of care for cancer patients by identifying high-impact cancer targets, defined as key oncogenic drivers or immune system activators. The company's strategy involves selecting optimal therapeutic modalities for these targets. Operating as a single reporting and operating segment, the company's core business is developing early-stage cancer therapeutics, aiming to address critical needs in oncology treatment. The company's pipeline consists of CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, CLN-617. |
| URL | https://www.cullinanoncology.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 14, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |